Compare CHEF & RCUS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | CHEF | RCUS |
|---|---|---|
| Founded | 1985 | 2015 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Food Distributors | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.5B | 2.8B |
| IPO Year | 2011 | 2018 |
| Metric | CHEF | RCUS |
|---|---|---|
| Price | $59.97 | $23.17 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 8 | 8 |
| Target Price | ★ $71.88 | $29.38 |
| AVG Volume (30 Days) | 351.5K | ★ 2.0M |
| Earning Date | 02-11-2026 | 02-24-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 55.09 | N/A |
| EPS | ★ 1.73 | N/A |
| Revenue | ★ $4,040,541,000.00 | $240,000,000.00 |
| Revenue This Year | $10.35 | N/A |
| Revenue Next Year | $7.09 | N/A |
| P/E Ratio | $35.18 | ★ N/A |
| Revenue Growth | ★ 8.88 | N/A |
| 52 Week Low | $45.00 | $6.50 |
| 52 Week High | $68.94 | $26.40 |
| Indicator | CHEF | RCUS |
|---|---|---|
| Relative Strength Index (RSI) | 38.72 | 52.69 |
| Support Level | $59.78 | $20.59 |
| Resistance Level | $63.54 | $24.16 |
| Average True Range (ATR) | 1.53 | 1.08 |
| MACD | -0.48 | -0.18 |
| Stochastic Oscillator | 3.20 | 72.37 |
The Chefs' Warehouse Inc is a specialty food distributor in metropolitan areas across the United States and Canada. The company's product portfolio is comprised of imported and local specialty food products such as cheese, cooking oils, chocolates, dried food, baking products, meats, and other food products. It operates via one reporting segment called Food Product Distribution. Operations are concentrated on the east, midwest, and west coasts of the U.S. The company provides service to restaurants, clubs, hotels, caterers, schools, bakeries, casinos, and specialty food stores.
Arcus Biosciences Inc is a clinical-stage biopharmaceutical company. It develops immunotherapies for the treatment of cancer. The company focuses on an ATP-adenosine pathway, which is a key driver of immunosuppression in the tumor microenvironment to create and optimize differentiated small-molecule immuno-oncology product candidates. Its product pipeline includes Domvanalimab, Etrumadenant, AB598, Casdatifan among others. Arcus conducts clinical trials for different types of cancers such as Lung, Colorectal, Pancreatic, and others. The company operates through a single segment which is the business of developing and commercializing immunotherapies.